Evidence map›Paper›PMID 36911677›Full record

ArticleFrontiers in immunology2023

Single-cell RNA-seq analysis identifies distinct myeloid cells in a case with encephalitis temporally associated with COVID-19 vaccination.

Masakazu Ishikawa, Yuki Shimada, Tatsuhiko Ozono, Hisatake Matsumoto, Hiroshi Ogura, Keigo Kihara, Hideki Mochizuki, Tatsusada Okuno, Shuhei Sakakibara, Makoto Kinoshita and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Masakazu IshikawaLaboratory of Human Immunology (Single Cell Genomics), WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.
Yuki ShimadaDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Tatsuhiko OzonoDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Hisatake MatsumotoCenter for Infectious Disease Education and Research, Osaka University, Osaka, Japan.
Hiroshi OguraDepartment of Traumatology and Acute Critical Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Keigo KiharaDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Hideki MochizukiDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Tatsusada OkunoDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Shuhei SakakibaraDepartment of Traumatology and Acute Critical Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Makoto KinoshitaDepartment of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan.
Daisuke OkuzakiLaboratory of Human Immunology (Single Cell Genomics), WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan.
The University of Osaka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently accumulating evidence has highlighted the rare occurrence of COVID-19 vaccination-induced inflammation in the central nervous system. However, the precise information on immune dysregulation related to the COVID-19 vaccination-associated autoimmunity remains elusive. Here we report a case of encephalitis temporally associated with COVID-19 vaccination, where single-cell RNA sequencing (scRNA-seq) analysis was applied to elucidate the distinct immune signature in the peripheral immune system. Peripheral blood mononuclear cells (PBMCs) were analyzed using scRNA-seq to clarify the cellular components of the patients in the acute and remission phases of the disease. The data obtained were compared to those acquired from a healthy cohort. The scRNA-seq analysis identified a distinct myeloid cell population in PBMCs during the acute phase of encephalitis. This specific myeloid population was detected neither in the remission phase of the disease nor in the healthy cohort. Our findings illustrate induction of a unique myeloid subset in encephalitis temporally associated with COVID-19 vaccination. Further research into the dysregulated immune signature of COVID-19 vaccination-associated autoimmunity including the cerebrospinal fluid (CSF) cells of central nervous system (CNS) is warranted to clarify the pathogenic role of the myeloid subset observed in our study.

Indexed as

COVID-19EncephalitisCOVID-19 VaccinesHumansLeukocytes, MononuclearMyeloid CellsSingle-Cell Gene Expression AnalysisVaccinationCOVID-19 VaccinesCOVID-19encephalitismyeloid cellssingle-cell RNA-seqvaccination

Identifiers

PMID36911677
PMCPMC9996085
OpenAlexW4321616559

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.